Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) EBIT : $-8.96 Mil (TTM As of Sep. 2015)

View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada EBIT?

Tribute Pharmaceuticals Canada's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2015 was $1.61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2015 was $-8.96 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tribute Pharmaceuticals Canada's annualized ROC % for the quarter that ended in Sep. 2015 was -3.00%. Tribute Pharmaceuticals Canada's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2015 was 640.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tribute Pharmaceuticals Canada's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2015 was -7.63%.

Tribute Pharmaceuticals Canada EBIT Historical Data

The historical data trend for Tribute Pharmaceuticals Canada's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tribute Pharmaceuticals Canada EBIT Chart

Tribute Pharmaceuticals Canada Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

EBIT

Get a 7-Day Free Trial

1.05

-1.47

-4.42

-5.98

-3.61

Tribute Pharmaceuticals Canada Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
EBIT	Get a 7-Day Free Trial															3.04	-0.34	-3.63	-6.60	1.61

Competitive Comparison of Tribute Pharmaceuticals Canada's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tribute Pharmaceuticals Canada's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tribute Pharmaceuticals Canada's EV-to-EBIT falls into.

Tribute Pharmaceuticals Canada EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.96 Mil.

Tribute Pharmaceuticals Canada (OTCPK:TBUFF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tribute Pharmaceuticals Canada's annualized ROC % for the quarter that ended in Sep. 2015 is calculated as:

	ROC % (Q: Sep. 2015 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2015 )	+	Invested Capital (Q: Sep. 2015 ))	/ count )
=	-2.284 * ( 1 - -18.15% )	/	( (95.78	+	84.047)	/ 2 )
=	-2.698546	/	89.9135
=	-3.00 %

where

	Invested Capital		(Q: Jun. 2015 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	95.425	-	17.172	-	( 14.234	-	max(0, 40.426	-	22.899	+	14.234	))
=	95.78

	Invested Capital		(Q: Sep. 2015 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	84.903	-	13.433	-	( 9.972	-	max(0, 31.522	-	18.945	+	9.972	))
=	84.047

Note: The Operating Income data used here is four times the quarterly (Sep. 2015) data.

2. Joel Greenblatt's definition of Return on Capital:

Tribute Pharmaceuticals Canada's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2015 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2015 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2015		Q: Sep. 2015
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	6.436	/	( ( (1.048 + max(-16.463, 0))	+	(0.961 + max(-8.228, 0)) )	/	2 )
=	6.436	/	( ( 1.048	+	0.961 )	/	2 )
=	6.436	/	1.0045
=	640.72 %

where Working Capital is:

	Working Capital		(Q: Jun. 2015 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.529	+	2.363	+	1.581)	-	(17.172	+	0	+	7.764)
=	-16.463

	Working Capital		(Q: Sep. 2015 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(5.298	+	2.439	+	0.969)	-	(13.433	+	0	+	3.501)
=	-8.228

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2015) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tribute Pharmaceuticals Canada's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2015 )
	=	-8.96	/	117.400
	=	-7.63 %

Tribute Pharmaceuticals Canada EBIT Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.stellarpharma.com

Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.

Executives

John M Gregory	director, 10 percent owner
Sj Strategic Investments Llc	10 percent owner
Joan P Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory	other: Member	340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines